Mental or Behavioral Dysfunction – Page 2

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

3 months ago talkbio0Tagged Alzheimer 's disease, biotech, CNS disorder, IPO, MapLight Therapeutics, MPLT, Nasdaq, Phase 2 Clinical Trials, Psychotic Disorders, Public Offering, Schizophrenia

MapLight Therapeutics; IPO; Initial Public Offering; Nasdaq; MPLT; Schizophrenia; Alzheimer’s disease psychosis; CNS disorders; Phase 2 clinical trials; Biotech

METiS BioTech Announces China’s First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

3 months ago talkbio0Tagged AiTEM, biotech, China, Clinical, Drug Formulation Process, Metis people, nanodelivery, PBA, Phase III, pseudobulbar, Pseudobulbar affect

METiS BioTech; AI; drug formulation; Phase III; pseudobulbar affect (PBA); China; nanodelivery; AiTEM; clinical milestone

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

3 months ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

3 months ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

3 months ago talkbio0Tagged AFFIRM-1, BNC210, Clinical Failure, Neuphoria, Phobia, Social, Post-Traumatic Stress Disorder, strategic review

Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD

Bicycle Health Grows Leadership Team to Expand Access for Justice-Involved Populations

3 months ago talkbio0Tagged Andy Thomas, Bicycle Health, Business Development, Criminal Justice, executive team, Leadership, Opioid Use Disorder, Steve Tomlin, virtual care

Bicycle Health; Leadership team; Executive team; Steve Tomlin; Business development; Criminal justice; Opioid use disorder; Virtual care; Manu Kuppalli; Andy Thomas

Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature

3 months ago talkbio0Tagged Adherence To Medication Regime, AI-enabled, Detection, digital health, Gestures, partnering with, Presenile dementia, Preventive monitoring, Remote, Roche (company), SafeBeing platform, Somatix, Wearable Electronic Devices

Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health